Aline Renneville

发表

Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies

E. Clappier, A. Stamatoullas, J. Vial, 2018, British journal of haematology.

Cooperating gene mutations in acute myeloid leukemia: a review of the literature

C. Preudhomme, P. Fenaux, N. Boissel, 2008, Leukemia.

Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN

Benjamin L Ebert, T. Mikkelsen, B. Ebert, 2018, Science.

New insights to the MLL recombinome of acute leukemias

M. Krzywinski, E. Clappier, B. Schäfer, 2009, Leukemia.

Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Claude Preudhomme, Robert Barouki, Serge Koscielny, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Disease evolution and outcomes in familial AML with germline CEBPA mutations.

J. Gribben, B. Porse, L. Bullinger, 2015, Blood.

BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia

B. Quesnel, E. Bertrand, C. Preudhomme, 2016, Oncotarget.

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial

H. Dombret, C. Preudhomme, N. Ifrah, 2015, Haematologica.

SET-NUP214 is a recurrent γδ lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL.

H. Dombret, E. Macintyre, C. Preudhomme, 2014, Blood.

SET-NUP 214 is a recurrent gd lineage-speci fi c fusion transcript associated with corticosteroid / chemotherapy resistance in adult TALL

H. Dombret, E. Macintyre, C. Preudhomme, 2014 .

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants

D. Steinemann, Alison M. Male, J. Fitzgibbon, 2020, Nature Communications.

High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis

B. Quesnel, C. Preudhomme, F. Bauters, 2006, Leukemia.

The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia

J. Cayuela, A. Baruchel, P. Cony-Makhoul, 2013, Medicine.

High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.

C. Flamant, G. Leverger, M. Labopin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

F. Pasquier, F. Rosselli, S. de Botton, 2021, HemaSphere.

Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations.

O. Abdel-Wahab, R. Bradley, Aline Renneville, 2020, Blood.

Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis

P. Cony-Makhoul, C. Bastard, C. Preudhomme, 2015, American journal of hematology.

Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis

F. Pasquier, E. Solary, O. Mir, 2018, Leukemia & lymphoma.

Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia

A. Baruchel, H. Cavé, C. Preudhomme, 2010, British journal of haematology.

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents

E. Solary, C. Preudhomme, P. Fenaux, 2018, EBioMedicine.

Linezolid induces ring sideroblasts

B. Quesnel, C. Preudhomme, J. Rossignol, 2013, Haematologica.

Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype.

J. Cayuela, H. Dombret, C. Preudhomme, 2005, Blood.

Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): evolution on hypomethylating agent therapy.

C. Preudhomme, Aline Renneville, C. Rose, 2011, Leukemia research.

Clonal expansion of T cells in patients with eosinophilic lung disease

V. Cottin, Aline Renneville, J. Kahn, 2011, Allergy.

Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia

B. Quesnel, E. Bertrand, C. Preudhomme, 2013, American journal of hematology.

Brief Report Results and Discussion

H. Dombret, C. Bastard, C. Preudhomme, 2022 .

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.

A. Baruchel, C. Preudhomme, H. Sobol, 2009, Blood.

Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.

C. Preudhomme, C. Gardin, P. Rousselot, 2012, Leukemia research.

Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study.

J. Bourhis, H. Dombret, B. Quesnel, 2011, Blood.

Extensive mutational status of genes and clinical outcome in pediatric acute myeloid leukemia

G. Leverger, M. Labopin, C. Preudhomme, 2010, Leukemia.

Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia

B. Quesnel, E. Leprêtre, E. Bertrand, 2014, Clinical Cancer Research.

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

J. Soulier, J. Cayuela, H. Dombret, 2010, Blood.

Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia

J. Cayuela, H. Dombret, C. Preudhomme, 2014, Haematologica.

normal acute myeloid leukemia mutations in cytogenetically IDH2 Differential prognosis impact of

H. Dombret, N. Boissel, Aline Renneville, 2013 .

Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

H. Dombret, C. Preudhomme, N. Boissel, 2011, Blood.

Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group.

H. Dombret, B. Quesnel, C. Preudhomme, 2015, Leukemia research.

Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1‐RUNX1T1 fusion quantification on genomic DNA

H. Dombret, C. Preudhomme, Aurélie Caillault, 2014, American journal of hematology.

Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience

J. Cayuela, H. Dombret, E. Macintyre, 2010, Leukemia.

Slow relapse in acute myeloid leukemia with inv(16) or t(16;16)

T. Clozel, C. Preudhomme, P. Fenaux, 2009, Haematologica.

A randomized phase II trial of azacitidine +/− epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

A. Stamatoullas, S. Chevret, E. Wattel, 2016, Haematologica.

SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias

D. Birnbaum, E. Solary, O. Bernard, 2013, Leukemia.

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.

C. Preudhomme, P. Fenaux, M. Sébert, 2014, Leukemia research.

BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients

N. Mounier, C. Preudhomme, G. Robert, 2012, Oncotarget.

Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia

J. Soulier, E. Clappier, H. Dombret, 2018, Leukemia.

Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation

C. Preudhomme, X. Thomas, Y. Bertrand, 2009, Leukemia.

Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine

B. Quesnel, A. Duhamel, C. Preudhomme, 2016, Leukemia.

Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders

P. Nurden, G. Leverger, R. Favier, 2016, Orphanet Journal of Rare Diseases.

Minimal Residual Disease Assessed by WT1 Expression and NPM1 Mutations Specific RQ-PCR Assays Identifies Patients with Distinct Outcomes in the ALFA 0701 Trial and Is Decreased by Treatment with Gemtuzumab Ozogamicin

J. Cayuela, H. Dombret, C. Preudhomme, 2012 .

Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML

B. Quesnel, I. Yakoub-Agha, A. Duhamel, 2017, Bone Marrow Transplantation.

Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial.

J. Bourhis, H. Dombret, B. Quesnel, 2012, Leukemia research.

Neurofibromatosis‐1 gene deletions and mutations in de novo adult acute myeloid leukemia

J. Soulier, H. Dombret, C. Preudhomme, 2013, American journal of hematology.

Cooperation of activating Ras/rtk signal transduction pathway mutations and inactivating myeloid differentiation gene mutations in M0 AML: a study of 45 patients

C. Preudhomme, P. Fenaux, Aline Renneville, 2006, Leukemia.

Quantification of JAK2V617F mutation by next‐generation sequencing technology

C. Preudhomme, E. Lippert, Aline Renneville, 2013, American journal of hematology.

P-121 BCL2L10 is associated with resistance to azacitidine (AZA) in MDS and AML, and is a possible target in resistant patients

L. Mannone, P. Fenaux, G. Robert, 2013 .

Prognostic Value of TP53 Gene Mutations in Higher Risk MDS Treated with Azacitidine

C. Preudhomme, P. Fenaux, L. Adès, 2012 .

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

A. Stamatoullas, S. Chevret, E. Wattel, 2019, Haematologica.

P-023 Incidence and prognostic value of TP53 mutations in IPSS low and INT 1 (lower risk) MDS with del 5q

C. Preudhomme, P. Fenaux, T. Cluzeau, 2013 .

Acute myeloid leukemia with translocation t(3;5): new molecular insights

C. Preudhomme, Aline Renneville, O. Nibourel, 2013, Haematologica.

Acute myeloid leukemia with translocation t ( 3 ; 5 ) : new molecular insight by

C. Preudhomme, Aline Renneville, O. Nibourel, 2013 .

B7‐H3 protein expression in acute myeloid leukemia

B. Quesnel, C. Preudhomme, C. Berthon, 2015, Cancer medicine.

JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders

C. Preudhomme, Aline Renneville, C. Rose, 2008, Leukemia.

Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis.

B. Quesnel, C. Preudhomme, E. Cornet, 2012, Leukemia research.

The MLL recombinome of acute leukemias in 2017

E. Clappier, J. Cayuela, V. V. D. van der Velden, 2017, Leukemia.

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

J. Cayuela, H. Dombret, S. Chevret, 2014, Oncotarget.

The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplication.

H. Dombret, C. Preudhomme, C. Gardin, 2009, Blood.

Recurrent in-frame insertion in C/EBPα TAD2 region is a polymorphism without prognostic value in AML

P. Amouyel, H. Dombret, D. Cottel, 2008, Leukemia.

Two Distinct Mechanisms Contribute to Granulomonocytic Hyperplasia in Chronic Myelomonocytic Leukemias (CMML)

E. Solary, W. Vainchenker, O. Bernard, 2012 .

Which AML Subsets Benefit from Leukemic Cell Priming during Chemotherapy? Long-Term Analysis of the ALFA-9802 GM-CSF Study

J. Bourhis, H. Dombret, C. Preudhomme, 2008 .

Wilms tumor 1 (WT1) gene mutations in pediatric T-cell malignancies

E. Clappier, H. Cavé, C. Preudhomme, 2009, Leukemia.

Real-time quantitative PCR (RQ-PCR) detection of minimal residual disease (MRD) by optimized WT1 assay to enhance risk stratification in acute myeloid leukemia (AML): A European leukemia net study [Abstract]

R. Hills, S. Schnittger, C. Preudhomme, 2007 .

Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations

S. Broutin, J. Delahousse, A. Paci, 2018, Leukemia.

Final Analysis of the ALFA 0701 Study

H. Dombret, S. Chevret, C. Preudhomme, 2014 .

Somatic mutations associated with leukemic progression of familial platelet disorder with predisposition to acute myeloid leukemia

O. Abdel-Wahab, R. Favier, H. Raslova, 2016, Leukemia.

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

A. Vekhoff, E. Solary, C. Preudhomme, 2011, Blood.

Letter to the editor: Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.

F. Pasquier, F. Rosselli, S. de Botton, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Comprehensive mutational profiling of core binding factor acute myeloid leukemia.

O. Abdel-Wahab, H. Dombret, G. Leverger, 2016, Blood.

LYMPHOID NEOPLASIA MYD88 L265P mutation in Waldenstrom macroglobulinemia

E. Bertrand, S. Tricot, Aline Renneville, 2013 .

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial

H. Dombret, S. Leprêtre, P. Chevallier, 2015, Haematologica.

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.

J. Cayuela, H. Dombret, S. Chevret, 2013, Blood.

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.

H. Dombret, S. Chevret, B. Quesnel, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

J. Cayuela, H. Dombret, C. Preudhomme, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

V. V. D. van der Velden, R. Hills, S. Schnittger, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Which AML subsets benefit from leukemic cell priming during chemotherapy? Long‐term analysis of the ALFA‐9802 GM‐CSF study

H. Dombret, C. Preudhomme, C. Gardin, 2010, Cancer.

Myelodysplastic syndromes and acute leukemia with genetic predispositions: a new challenge for hematologists

C. Preudhomme, Aline Renneville, S. Lejeune, 2016, Expert review of hematology.

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association

H. Dombret, C. Preudhomme, P. Fenaux, 2011, Leukemia.

Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group.

H. Dombret, B. Quesnel, C. Preudhomme, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia

H. Dombret, C. Preudhomme, X. Thomas, 2009, Cancer.

Copy-number analysis identified new prognostic marker in acute myeloid leukemia

J. Soulier, H. Dombret, B. Quesnel, 2017, Leukemia.

Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia

X Thomas, H. Dombret, C. Preudhomme, 2011, Leukemia.

Chronic myelomonocytic leukemia diagnosis and management

E. Padron, Aline Renneville, O. Chan, 2021, Leukemia.

EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression.

Matthew C. Canver, S. Orkin, B. Bernstein, 2015, Blood.

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia

H. Dombret, J. Bibault, C. Preudhomme, 2015, Oncotarget.

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

Claude Preudhomme, Daniel Birnbaum, Olivier Kosmider, 2012, Blood.

High DNA Methyltransferase DNMT3B Levels: A Poor Prognostic Marker in Acute Myeloid Leukemia

G. Salles, A. Plesa, J. Magaud, 2012, PloS one.

Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.

O. Abdel-Wahab, H. Dombret, G. Leverger, 2014, Blood.

Frequent ASXL 2 mutations in acute myeloid leukemia patients with t ( 8 ; 21 ) / RUNX 1-RUNX 1 T 1 chromosomal translocations

O. Abdel-Wahab, H. Dombret, G. Leverger, 2014 .

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

A. Stamatoullas, P. Cony-Makhoul, S. Chevret, 2016, Leukemia.

Lenalidomide with or without Erythropoietin in transfusion dependent erythropoiesis-stimulating agent-refractory lower risk MDS without 5 q deletion Running title : Lenalidomide in transfused non del 5 q low risk MDS

Stanislas, Taksin, A. Stamatoullas, 2015 .

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group

H. Dombret, C. Preudhomme, X. Thomas, 2018, Haematologica.

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

H. Dombret, B. Quesnel, C. Preudhomme, 2015, Oncotarget.

The MLL recombinome of acute leukemias in 2013

W. Choi, S. Bohlander, E. Clappier, 2013, Leukemia.

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants

D. Steinemann, Alison M. Male, J. Fitzgibbon, 2020, Nature Communications.

Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival

J. Fitzgibbon, J. Cavenagh, C. Preudhomme, 2012, Haematologica.

Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia

C. Preudhomme, Aline Renneville, J. Laï, 2008, Genes, chromosomes & cancer.

MYD88 L265P mutation in Waldenstrom macroglobulinemia.

B. Quesnel, E. Bertrand, C. Preudhomme, 2012, Blood.

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.

A. Stamatoullas, E. Solary, S. Chevret, 2016, Blood.

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

D. Birnbaum, T. Haferlach, E. Solary, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence and Prognostic Value of TP53 Mutations in Lower Risk MDS with Del 5q.

A. Stamatoullas, C. Bastard, C. Preudhomme, 2012 .

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

D. Birnbaum, S. Miyano, Y. Shiraishi, 2013, Blood.

Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML

H. Dombret, B. Quesnel, C. Preudhomme, 2021, Leukemia.

Assessment of Minimal Residual Disease in Standard-Risk AML.

L. Adès, Aline Renneville, Sarah Morin-Zorman, 2016, The New England journal of medicine.

Clonal architecture of chronic myelomonocytic leukemias.

E. Solary, W. Vainchenker, O. Bernard, 2013, Blood.

Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study

F. Pasquier, E. Clappier, S. Broutin, 2020, Leukemia & lymphoma.

TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia

B. Quesnel, E. Bertrand, C. Preudhomme, 2017, Clinical Cancer Research.

Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial

Sylvie Chevret, Claude Preudhomme, Hassan Farhat, 2014, Oncotarget.

Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia

E. Solary, M. Patnaik, E. Padron, 2021, Leukemia.

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

D. Birnbaum, E. Solary, O. Bernard, 2013 .

MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations.

D. Bluteau, C. Deswarte, G. Leverger, 2012, Blood.

Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse

C. Preudhomme, P. Rousselot, Aline Renneville, 2014, American journal of hematology.

Prévention des complications liées au traitement des hémopathies Prevention of treatment-related side effects in hematology

I. Yakoub-Agha, X. Leleu, T. Facon, 2005 .

Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines

P. Rohrlich, N. Mounier, C. Preudhomme, 2014, Oncotarget.

Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation

B. Quesnel, C. Preudhomme, Aline Renneville, 2007, Leukemia.

Prognostic value of monocyte subset distribution in chronic myelomonocytic leukemia: results of a multicenter study

E. Solary, C. Preudhomme, P. Fenaux, 2020, Leukemia.

Exome analysis of treatment‐related AML after APL suggests secondary evolution

Christopher A. Miller, J. Welch, S. Heath, 2018, British journal of haematology.

Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors.

A. Italiano, F. Barlesi, L. Lacroix, 2023, JCO precision oncology.

Le séquençage de nouvelle génération (NGS) a-t-il déjà sa place dans nos laboratoires d’oncohématologie ?

Aline Renneville, T. Boyer, C. Preudhomme, 2013 .

Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies.

S. Carr, B. Ebert, J. Cayuela, 2021, Cancer discovery.

Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies.

S. Carr, B. Ebert, J. Cayuela, 2021, Blood cancer discovery.

BCOR and BCORL 1 mutations in myelodysplastic syndromes and related disorders

D. Birnbaum, S. Miyano, Y. Shiraishi, 2013 .

Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21)

O. Abdel-Wahab, H. Dombret, G. Leverger, 2016, Leukemia & lymphoma.

Aline Renneville, J. Micol, E. Bernard, 2023, Bulletin du Cancer.

Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes.

C. Preudhomme, P. Fenaux, L. Adès, 2015, Leukemia research.

Gene Mutations and Minimal Residual Disease (MRD) As Predictors of Remission Duration in Adults with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Treated with High-Dose Cytarabine (HDAC) - First Results of the Prospective French Intergroup CBF-2006 Trial

J. Cayuela, H. Dombret, M. Béné, 2011 .

F. Pasquier, F. Rosselli, S. de Botton, 2021, Annals of Oncology.

Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacytidine (AZA)

B. Quesnel, C. Preudhomme, P. Fenaux, 2014 .